RecruitingNot ApplicableNCT03364296

Biological Dating of Cerebral Ischemia With GST-π/PRDX1 to Detect Patients With Stroke of Unknown Onset Within the Therapeutic Window of Thrombolysis

Biological Dating of Cerebral Ischemia With Glutathion S-Transferase-π (GST-π) and Peroxyredoxin 1 (PRDX1) to Detect Patients With Stroke of Unknown Onset Within the Therapeutic Window of Thrombolysis


Sponsor

Central Hospital, Nancy, France

Enrollment

930 participants

Start Date

Oct 15, 2018

Study Type

INTERVENTIONAL

Conditions

Summary

The FLAG1 study will assess the diagnostic performance of biomarkers Glutathion S-Transferase-π (GST-π) and Peroxyredoxin 1 (PRDX1) to identify cerebral infarction of less than 4,5 hours in a population of patients with neurological deficiency of less than 12 hours.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Patients over 18 years old
  • Patients with symptoms consistent with stroke and a National Institute of Health Stroke Score ≥3 at the inclusion time
  • For patients with time of symptom onset is <4.5h at inclusion, the time of symptom onset has to be precisely known, with a margin of error not exceeding 30 minutes (through patient or witness interview)
  • last time patient presented no deficit must be less than 24 hours,
  • symptoms must have been first recognized more than 4.5 hours before blood draw.
  • Possibility to perform MRI within the 30 minutes following blood collection
  • Person affiliated to or beneficiary of a social security plan

Exclusion Criteria6

  • Persons referred in articles L.1121-5, L.1121-7, L.1121-8 and L.1122-2 of the French Public Health Code: Pregnant, parturient or breastfeeding woman ; Minor person (non-emancipated) ; Adult person under legal protection (any form of public guardianship) ; Adult person incapable of giving consent and not under legal protection.
  • Persons deprived of liberty for judicial or administrative decision.
  • Persons subject to psychiatric care under articles L.3212-1 and L.3213-1 of the French Public Health Code.
  • Known cancer in progression.
  • Known cirrhosis.
  • Myocardial Infarctions, stroke, Subarachnoid hemorrhage or intracranial injury within 3 months prior to enrolment.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBlood Samples

Blood sample retrieved for biological assessment and biobanking


Locations(5)

Centre Hospitalier de Bar-Le-Duc

Bar-le-Duc, France

Hôpital Central

Nancy, France

Fondation Adolphe de Rothschild

Paris, France

Centre Hospitalier de Troyes

Troyes, France

Centre Hospitalier de Verdun

Verdun, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03364296


Related Trials